Visão geral da empresa
LeonaBio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of small molecules aimed at restoring neuronal health and decelerating neurodegeneration. The company functions within the healthcare sector, specifically targeting the biotechnology industry, where its primary focus is on advancing therapeutic solutions for neurological conditions. According to the available data, the company employs a workforce of 26 individuals and maintains a market capitalization of $26.62 million. The reported annual revenue is listed as N/A, indicating that the firm has not yet generated significant commercial sales to date. This combination of a sub-$30 million market cap, zero reported revenue, and a small employee base suggests that LeonaBio, Inc. is a pre-revenue entity relying heavily on external capital to fund its research and development pipeline. The absence of substantial revenue figures places the company in a typical early-stage development profile, where value is derived from potential asset approval rather than current operational earnings. Consequently, the market cap reflects investor sentiment regarding the future potential of its clinical trials rather than established business performance or cash flow generation.
Saúde financeira
The financial performance metrics for LeonaBio, Inc. reveal a net income of $-37,723,000 over the trailing twelve months, while the company reported an EBITDA of $-38,295,000 and revenue data marked as N/A. The substantial negative net income relative to the negligible or zero revenue indicates a cost structure dominated by research and development expenses and operational overheads typical of pre-commercial biotechnology firms. The company generated a free cash flow of $-30,363,876, which signifies a continuous consumption of cash reserves required to sustain clinical trial operations and administrative functions. In terms of profitability margins, the gross margin stands at 0.0%, the operating margin is 0.0%, and the profit margin is also 0.0%, reflecting the lack of commercial sales volume to generate traditional profitability. Regarding liquidity and leverage, the firm holds $25.23 million in cash against $912,000 in total debt, resulting in a debt-to-equity ratio of 3.40. Despite the elevated debt-to-equity figure, the balance sheet is not highly leveraged in a distress sense because the debt amount is trivial compared to the cash on hand. The current ratio is reported at 9.70, a figure that indicates extremely strong short-term liquidity and an ample ability to cover immediate obligations with available current assets. Finally, the return on equity is -89.4% and the return on assets is -42.2%, metrics that reveal management is currently operating with negative returns on capital due to the heavy investment phase of the business model.
Avaliação de valorização
Valuation metrics for LeonaBio, Inc. show a trailing P/E ratio of N/A and a forward P/E of -4.14, a difference that implies the market is pricing the stock based on future expectations of profitability that have not yet materialized. The price-to-book ratio is 0.99, suggesting that the market is currently valuing the company's equity at approximately its book value rather than applying a significant premium. The price-to-sales ratio is listed as N/A, and the enterprise value to EBITDA is -0.04, both of which indicate that traditional valuation multiples are not applicable due to the lack of positive earnings or sales data. The stock has traded with a 52-week high of $8.36 and a 52-week low of $2.20, meaning the current price sits somewhere within this range, subject to market volatility. The beta value is 2.80, which indicates that the stock price is significantly more volatile than the broader market, moving with high sensitivity to market fluctuations. Investors must recognize that the negative forward P/E and the absence of sales-based multiples reflect the high-risk, high-reward nature of investing in a clinical-stage company with no current revenue stream.
Growth & Income
The revenue growth year-over-year is N/A, and the earnings growth year-over-year is also N/A, as the company has not yet achieved commercial milestones necessary to calculate growth rates. Since the revenue and earnings are not positive, there is no growth trajectory to compare against revenue expansion, and the company remains in a stage where earnings growth is contingent upon successful clinical trial outcomes and future commercialization. LeonaBio, Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources into its drug development pipeline rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology firms in the development phase, as capital is prioritized for advancing clinical candidates like ATH-1105 and ATH-1020 rather than providing income distributions. The overall growth and income profile is characterized by zero current income generation and an exclusive focus on capital allocation toward research and development activities to potentially unlock future value.